Pulmonary arterial hypertension: the burden of disease and impact on quality of life.

In the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study (ARIES)-1, the endothelin receptor antagonist ambrisentan was associated with significant improvement in the SF-36 physical functioning domain at 12 weeks (p=0.005), whereas a trend towards improvement in SF-36-measured health domains did not reach statistical significance in ARIES-2 [ 47 ].

also in 111,027 other papers